• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

J&J, Pro­tag­o­nist re­veal two Phase 3 wins for oral IL-23 drug that's ex­pect­ed to be a block­buster

5 months ago
R&D

Bris­tol My­ers takes on au­toim­mune dis­eases with cell ther­a­py, plus new da­ta from Ca­balet­ta and Kyver­na

5 months ago
R&D
Cell/Gene Tx

Bay­er, Cy­to­ki­net­ics make a deal in Japan; Ex-Car­mot CEO to run LB Phar­ma­ceu­ti­cals

5 months ago
News Briefing

Law­mak­ers are pok­ing holes in phar­ma's fa­vorite new way to mar­ket med­i­cines

5 months ago
Pharma
In Focus

Drug­mak­ers 'not do­ing every­thing that they could' to widen glob­al ac­cess, new re­port finds

5 months ago
Pharma

For­mer NCI di­rec­tor teams up with se­r­i­al en­tre­pre­neur for $70M VC fund tar­get­ing 'su­per-ear­ly' sci­ence

5 months ago
Financing
Startups

Mer­ck fi­nal­ly has sub­cu­ta­neous Keytru­da re­sults, and it's go­ing to reg­u­la­tors

5 months ago
R&D
Pharma

In­cyte’s bet on Escient hits a snag as safe­ty is­sues ham­per Phase 2 chron­ic hives tri­al

5 months ago
R&D

Ex­clu­sive: Synap­ti­c­ure rais­es $25M for its ap­proach to vir­tu­al neu­rode­gen­er­a­tive dis­ease care

5 months ago
Financing
Pharma

Ex­clu­sive: Ji­mi­ni Health launch­es with $8M for AI-as­sist­ed ther­a­py

5 months ago
Health Tech

Bio­gen, UCB de­tail re­sponse rates in Phase 3 lu­pus tri­al af­ter sur­pris­ing suc­cess

5 months ago
R&D

Vir, Blue­jay in­vig­o­rate he­pati­tis D space with new da­ta

5 months ago
R&D

Rock­et shares promis­ing long-term re­sults from rare heart dis­ease gene ther­a­py in small study

5 months ago
R&D
Cell/Gene Tx

Neu­ro­gene pa­tient had life-threat­en­ing side ef­fect in Rett syn­drome study

5 months ago
R&D
Cell/Gene Tx

Syn­dax's Re­vu­forj wins FDA ap­proval in ag­gres­sive form of leukemia

5 months ago
Pharma
FDA+

CSL Behring will close Cal­i­for­nia of­fice as part of shrink­ing ex vi­vo work

5 months ago
People
Cell/Gene Tx

FDA of­fers more guid­ance on de­vel­op­ing cell and gene ther­a­pies

5 months ago
Cell/Gene Tx
FDA+

Re­genxbio shares first da­ta show­ing Duchenne gene ther­a­py im­proves mus­cle func­tion

5 months ago
R&D

A rare neu­ro­log­i­cal dis­ease is Sage’s last, best hope af­ter fail­ures in de­pres­sion

5 months ago
R&D
Pharma

As car­diomy­opa­thy mar­ket ex­pands, Al­ny­lam of­fers look at Phase 1 da­ta in healthy vol­un­teers

5 months ago
R&D

Aclaris makes a deal, aims to raise $80M; Em­me­cell’s Ph1 up­date in corneal ede­ma

5 months ago
News Briefing

At­las Ven­ture tar­gets $450M for 14th biotech fund, the same size as its 2022 raise

5 months ago
Financing
Startups

No­var­tis strikes ra­dio­phar­ma deal with Ra­tio worth up to $745M

5 months ago
Startups
Deals

Cy­bin says its psy­che­del­ic drug can sus­tain re­mis­sion in de­pres­sion pa­tients

5 months ago
R&D
First page Previous page 63646566676869 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.